Ayurvedic medicinal plants for Alzheimer's disease: A review

Alzheimer's Research and Therapy

Volumn 4, Issue 3, 2012, Pages

  Rao, Rammohan V ^a   Descamps, Olivier ^a   John, Varghese ^a   Bredesen, Dale E ^a,b  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; AMYLOID BETA PROTEIN; ASHWAGANDHA EXTRACT; ASIATIC ACID; ASIATICOSIDE; AYURVEDIC DRUG; BACOPA MONNIERI EXTRACT; BACOSAPONIN DERIVATIVE; CELASTRUS PANICULATUS EXTRACT; CENTELLA ASIATICA EXTRACT; CONVOLVULUS PLURICAULIS EXTRACT; CURCUMA LONGA EXTRACT; DEHYDROWITHANOLIDE R; MEDICATED OIL; NARDOSTACHYS JATAMANSI EXTRACT; NOOTROPIC AGENT; OIL; PHYTOSTEROL; PLANT EXTRACT; REACTIVE OXYGEN METABOLITE; SAPONIN DERIVATIVE; TRITERPENOID; UNCLASSIFIED DRUG; WITHAFERIN A; WITHANOLIDE; WITHANONE; WITHASOMIDIENONE; WITHASOMNIFERIN A; WITHASOMNIFEROL A; WITHASOMNIFEROL B; WITHASOMNIFEROL C;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTHMA; AYURVEDA; BACOPA MONNIERI; BLOOD BRAIN BARRIER; CELASTRUS PANICULATUS; CELL DEATH; CENTELLA ASIATICA; COGNITIVE DEFECT; CONVOLVULUS PLURICAULIS; CURCUMA LONGA; DRUG ISOLATION; DRUG MECHANISM; DRUG RESEARCH; EPILEPSY; GUGGULU; HUMAN; INSOMNIA; LEARNING; LIPID PEROXIDATION; MASSAGE; MEMORY; NARDOSTACHYS JATAMANSII; NERVE FIBER GROWTH; NEUROPHARMACOLOGY; NEUROTOXICITY; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; RHEUMATIC DISEASE; WITHANIA SOMNIFERA;

EID: 84862584005     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt125     Document Type: Article

References (113)

1. 2010 Alzheimer's disease facts and figures. Alzheimer's Association, Alzheimers Dement 6 158 194 20298981
2. Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence. Bredesen DE, Mol Neurodegener 2009 4 27 10.1186/1750-1326-4-27 19558683
3. Alzheimer's disease: part 2 - A botanical treatment plan. Alternative and Complementary Therapies. Abascal K, Yarnell E, 2004 10 67 72
4. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS, J Pharm Pharmacol 1999 51 527 534 10411211 (Pubitemid 29319777)
5. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Howes MJ, Perry NS, Houghton PJ, Phytother Res 2003 17 1 18 10.1002/ptr.1280 12557240 (Pubitemid 36205453)
6. Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function. Kennedy DO, Wightman EL, Adv Nutr 2011 2 32 50 22211188
7. Potential medicinal plants for CNS disorders: an overview. Kumar V, Phytother Res 2006 20 1023 1035 10.1002/ptr.1970 16909441 (Pubitemid 44951704)
8. Dementia in Ayurveda. Manyam BV, J Altern Complement Med 1999 5 81 88 10.1089/acm.1999.5.81 10100034 (Pubitemid 29180804)
9. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Mishra LC, Singh BB, Dagenais S, Altern Med Rev 2000 5 334 346 10956379 (Pubitemid 30660827)
10. Alternative medicine and Alzheimer disease. Kelley BJ, Knopman DS, Neurologist 2008 14 299 306 10.1097/NRL.0b013e318172cf4d 18784599
11. Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Wollen KA, Altern Med Rev 2010 15 223 244 21155625
12. Indian medicinal plants as antiradicals and DNA cleavage protectors. Russo A, Izzo AA, Cardile V, Borrelli F, Vanella A, Phytomedicine 2001 8 125 132 10.1078/0944-7113-00021 11315755 (Pubitemid 32267097)
13. Monograph. Withania somnifera. Altern Med Rev 2004 9 211 214 15253680
14. A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: a double-blind randomized, placebo-controlled study. Auddy B, Hazra J, Mitra A, Abedon B, Ghosal S, J Am Nutra Assoc 2008 11 50 56
15. Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian Withania somnifera DUNAL. and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. Matsuda H, Murakami T, Kishi A, Yoshikawa M, Bioorg Med Chem 2001 9 1499 1507 10.1016/S0968-0896(01)00024-4 11408168 (Pubitemid 32633968)
16. Effect of ashwagandha on lipid peroxidation in stress-induced animals. Dhuley JN, J Ethnopharmacol 1998 60 173 178 10.1016/S0378-8741(97)00151-7 9582008 (Pubitemid 28143728)
17. Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's disease. Jayaprakasam B, Padmanabhan K, Nair MG, Phytother Res 2010 24 859 863 19957250
18. Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. Parihar MS, Hemnani T, J Biosci 2003 28 121 128 10.1007/BF02970142 12682435 (Pubitemid 36268257)
19. An aqueous extract of Withania somnifera root inhibits amyloid beta fibril formation in vitro. Kumar S, Harris RJ, Seal CJ, Okello EJ, Phytother Res 2012 26 113 117 10.1002/ptr.3512 21567509
20. Search for natural products related to regeneration of the neuronal network. Tohda C, Kuboyama T, Komatsu K, Neurosignals 2005 14 34 45 10.1159/000085384 15956813 (Pubitemid 40868982)
21. Axon- or dendrite-predominant outgrowth induced by constituents from Ashwagandha. Kuboyama T, Tohda C, Zhao J, Nakamura N, Hattori M, Komatsu K, Neuroreport 2002 13 1715 1720 10.1097/00001756-200210070-00005 12395110 (Pubitemid 35333148)
22. Systemic administration of defined extracts from Withania somnifera (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, Bigl V, Neurochem Int 1997 30 181 190 10.1016/S0197-0186(96)00025-3 9017665 (Pubitemid 27029176)
23. Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. Tohda C, Kuboyama T, Komatsu K, Neuroreport 2000 11 1981 1985 10.1097/00001756-200006260-00035 10884056 (Pubitemid 30429148)
24. Neuritic regeneration and synaptic reconstruction induced by withanolide A. Kuboyama T, Tohda C, Komatsu K, Br J Pharmacol 2005 144 961 971 10.1038/sj.bjp.0706122 15711595 (Pubitemid 40593022)
25. Curcumin: the Indian solid gold. Aggarwal BB, Sundaram C, Malani N, Ichikawa H, Adv Exp Med Biol 2007 595 1 75 10.1007/978-0-387-46401-5-1 17569205
26. Curcumin: getting back to the roots. Shishodia S, Sethi G, Aggarwal BB, Ann N Y Acad Sci 2005 1056 206 217 10.1196/annals.1352.010 16387689 (Pubitemid 43030979)
27. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA, J Pharmacol Exp Ther 2008 326 196 208 10.1124/jpet.108.137455 18417733 (Pubitemid 351872144)
28. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). Chainani-Wu N, J Altern Complement Med 2003 9 161 168 10.1089/107555303321223035 12676044 (Pubitemid 36297021)
29. Apolipoprotein E polymorphism and Alzheimer disease: The Indo-US Cross-National Dementia Study. Ganguli M, Chandra V, Kamboh MI, Johnston JM, Dodge HH, Thelma BK, Juyal RC, Pandav R, Belle SH, DeKosky ST, Arch Neurol 2000 57 824 830 10.1001/archneur.57.6.824 10867779 (Pubitemid 30397184)
30. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM, Neurobiol Aging 1995 16 523 530 10.1016/0197-4580(95)00049-K 8544901
31. Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautschy SA, Neurobiol Aging 2005 26 Suppl 1 133 136 16266772
32. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM, J Neurosci 2001 21 8370 8377 11606625 (Pubitemid 33051435)
33. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM, J Biol Chem 2005 280 5892 5901 15590663 (Pubitemid 40280072)
34. Nutritional approaches to combat oxidative stress in Alzheimer's disease. Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V, J Nutr Biochem 2002 13 444 10.1016/S0955-2863(02)00205-X 12165357 (Pubitemid 34876979)
35. NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program, Natl Toxicol Program Tech Rep Ser 1993 427 1 275 12616304
36. ClinicalTrials.gov homepage. http://clinicaltrials.gov/
37. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V, J Clin Psychopharmacol 2008 28 110 113 10.1097/jcp.0b013e318160862c 18204357
38. Challenges associated with curcumin therapy in Alzheimer disease. Belkacemi A, Doggui S, Dao L, Ramassamy C, Expert Rev Mol Med 2011 13 34 22051121
39. Bacopa monniera. Monograph. Altern Med Rev 2004 9 79 85 15005647
40. Bacopa monniera, a reputed nootropic plant: an overview. Russo A, Borrelli F, Phytomedicine 2005 12 305 317 10.1016/j.phymed.2003.12.008 15898709 (Pubitemid 40471030)
41. Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera. Dhanasekaran M, Tharakan B, Holcomb LA, Hitt AR, Young KA, Manyam BV, Phytother Res 2007 21 965 969 10.1002/ptr.2195 17604373 (Pubitemid 47582771)
42. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, Wesnes K, Nathan PJ, Phytother Res 2008 22 1629 1634 10.1002/ptr.2537 18683852
43. Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. Singh RH, Narsimhamurthy K, Singh G, Biogerontology 2008 9 369 374 10.1007/s10522-008-9185-z 18931935
44. Exploring the role of 'Brahmi' (Bocopa monnieri and Centella asiatica) in brain function and therapy. Shinomol GK, Bharath MM, Recent Pat Endocr Metab Immune Drug Discov 2011 5 33 49 10.2174/187221411794351833 22074576
45. Effect of Bacopa monniera Linn. (brahmi) extract on avoidance responses in rat. Singh HK, Dhawan BN, J Ethnopharmacol 1982 5 205 214 10.1016/0378-8741(82)90044-7 7057659 (Pubitemid 12126680)
46. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K, J Ethnopharmacol 2010 127 26 31 10.1016/j.jep.2009.09.056 19808086
47. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S, Phytother Res 2000 14 174 179 10.1002/(SICI)1099-1573(200005)14:3<174::AID-PTR624>3. 0.CO;2-O 10815010 (Pubitemid 30326010)
48. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. Limpeanchob N, Jaipan S, Rattanakaruna S, Phrompittayarat W, Ingkaninan K, J Ethnopharmacol 2008 120 112 117 10.1016/j.jep.2008.07.039 18755259
49. Safety evaluation of BacoMind in healthy volunteers: a phase I study. Pravina K, Ravindra KR, Goudar KS, Vinod DR, Joshua AJ, Wasim P, Venkateshwarlu K, Saxena VS, Amit A, Phytomedicine 2007 14 301 308 10.1016/j.phymed.2007.03.010 17442556 (Pubitemid 46654793)
50. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J, Neuropsychopharmacology 2002 27 279 281 10.1016/S0893-133X(01)00419-5 12093601 (Pubitemid 34686978)
51. The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Nathan PJ, Clarke J, Lloyd J, Hutchison CW, Downey L, Stough C, Hum Psychopharmacol 2001 16 345 351 10.1002/hup.306 12404571 (Pubitemid 32655170)
52. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ, Psychopharmacology (Berl) 2001 156 481 484 10.1007/s002130100815 (Pubitemid 32695859)
53. Effect of Brahmi Rasayan on the central nervous system. Shukia B, Khanna NK, Godhwani JL, J Ethnopharmacol 1987 21 65 74 10.1016/0378-8741(87)90095-X 3695557 (Pubitemid 18082813)
54. Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain. Bihaqi SW, Sharma M, Singh AP, Tiwari M, J Ethnopharmacol 2009 124 409 415 10.1016/j.jep.2009.05.038 19505562
55. Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi. Malik J, Karan M, Vasisht K, Pharm Biol 2011 49 1234 1242 10.3109/13880209.2011.584539 21846173
56. The Ayurvedic medicine Clitoria ternatea - from traditional use to scientific assessment. Mukherjee PK, Kumar V, Kumar NS, Heinrich M, J Ethnopharmacol 2008 120 291 301 10.1016/j.jep.2008.09.009 18926895 (Pubitemid 50320604)
57. Clitoria ternatea and the CNS. Jain NN, Ohal CC, Shroff SK, Bhutada RH, Somani RS, Kasture VS, Kasture SB, Pharmacol Biochem Behav 2003 75 529 536 10.1016/S0091-3057(03)00130-8 12895670 (Pubitemid 36936887)
58. An update on Shankhpushpi, a cognition-boosting Ayurvedic medicine. Sethiya NK, Nahata A, Mishra SH, Dixit VK, Zhong Xi Yi Jie He Xue Bao 2009 7 1001 1022 10.3736/jcim20091101 19912732
59. Effect of Convulvulus pluricaulis Choisy. on learning behaviour and memory enhancement activity in rodents. Nahata A, Patil UK, Dixit VK, Nat Prod Res 2008 22 1472 1482 10.1080/14786410802214199 19023811
60. Effect of Evolvulus alsinoides Linn. on learning behavior and memory enhancement activity in rodents. Nahata A, Patil UK, Dixit VK, Phytother Res 2010 24 486 493 19610035
61. Effect of Convolvulus pluricaulis Choisy and Asparagus racemosus Willd on learning and memory in young and old mice: a comparative evaluation. Sharma K, Bhatnagar M, Kulkarni SK, Indian J Exp Biol 2010 48 479 485 20795365
62. Clitoria ternatea root extract enhances acetylcholine content in rat hippocampus. Rai KS, Murthy KD, Karanth KS, Nalini K, Rao MS, Srinivasan KK, Fitoterapia 2002 73 685 689 10.1016/S0367-326X(02)00249-6 12490229 (Pubitemid 35477766)
63. Clitoria ternatea (Linn) root extract treatment during growth spurt period enhances learning and memory in rats. Rai KS, Murthy KD, Karanth KS, Rao MS, Indian J Physiol Pharmacol 2001 45 305 313 11881569 (Pubitemid 32776798)
64. Influence of Clitoria ternatea extracts on memory and central cholinergic activity in rats. Taranalli AD, Cheeramkuzhy TC, Pharm Biol 2000 38 51 56 21214440 (Pubitemid 30166980)
65. Altered dendritic arborization of amygdala neurons in young adult rats orally intubated with Clitorea ternatea aqueous root extract. Rai KS, Murthy KD, Rao MS, Karanth KS, Phytother Res 2005 19 592 598 10.1002/ptr.1657 16161034 (Pubitemid 41375241)
66. [Plant metabolites as nootropics and cognitives]. Cervenka F, Jahodar L, Ceska Slov Farm 2006 55 219 229 Article in Czech 17128592
67. Centella asiatica extract selectively decreases amyloid beta levels in hippocampus of Alzheimer's disease animal model. Dhanasekaran M, Holcomb LA, Hitt AR, Tharakan B, Porter JW, Young KA, Manyam BV, Phytother Res 2009 23 14 19 10.1002/ptr.2405 19048607
68. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, Barreiro EJ, Viegas C Jr, CNS Neurol Disord Drug Targets 2011 10 251 270 20874701
69. Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats. Veerendra Kumar MH, Gupta YK, Clin Exp Pharmacol Physiol 2003 30 336 342 10.1046/j.1440-1681.2003.03842.x 12859423 (Pubitemid 36713989)
70. Gotu Kola (Centella asiatica) extract enhances phosphorylation of cyclic AMP response element binding protein in neuroblastoma cells expressing amyloid beta peptide. Xu Y, Cao Z, Khan I, Luo Y, J Alzheimers Dis 2008 13 341 349 18431001 (Pubitemid 352039032)
71. Nootropic activity of Celastrus paniculatus seed. Bhanumathy M, Harish MS, Shivaprasad HN, Sushma G, Pharm Biol 2010 48 324 327 10.3109/ 13880200903127391 20645820
72. Celastrus paniculatus seed water soluble extracts protect cultured rat forebrain neuronal cells from hydrogen peroxide-induced oxidative injury. Godkar P, Gordon RK, Ravindran A, Doctor BP, Fitoterapia 2003 74 658 669 10.1016/S0367-326X(03)00190-4 14630170 (Pubitemid 37443454)
73. Celastrus paniculatus seed water soluble extracts protect against glutamate toxicity in neuronal cultures from rat forebrain. Godkar PB, Gordon RK, Ravindran A, Doctor BP, J Ethnopharmacol 2004 93 213 219 10.1016/j.jep.2004.03.051 15234755 (Pubitemid 38962407)
74. Celastrus paniculatus seed oil and organic extracts attenuate hydrogen peroxide- and glutamate-induced injury in embryonic rat forebrain neuronal cells. Godkar PB, Gordon RK, Ravindran A, Doctor BP, Phytomedicine 2006 13 29 36 10.1016/j.phymed.2003.11.011 16360930 (Pubitemid 41797588)
75. Antioxidant property of Celastrus paniculatus willd.: a possible mechanism in enhancing cognition. Kumar MH, Gupta YK, Phytomedicine 2002 9 302 311 10.1078/0944-7113-00136 12120811 (Pubitemid 34712501)
76. Structure and stereochemistry of nardostachysin, a new terpenoid ester constituent of the rhizomes of Nardostachys jatamansi. Chatterjee A, Basak B, Saha M, Dutta U, Mukhopadhyay C, Banerji J, Konda Y, Harigaya Y, J Nat Prod 2000 63 1531 1533 10.1021/np990503m 11087600
77. Jatamols A and B: Sesquiterpenoids of Nardostachys jatamansi Roots1. Bagchi A, Oshima Y, Hikino H, Planta Med 1991 57 282 283 10.1055/s-2006-960091 17226161
78. Neolignans and Lignans of Nardostachys jatamansi Roots1. Bagchi A, Oshima Y, Hikino H, Planta Med 1991 57 96 97 10.1055/s-2006-960037 17226134
79. The role of antioxidant properties of Nardostachys jatamansi in alleviation of the symptoms of the chronic fatigue syndrome. Lyle N, Gomes A, Sur T, Munshi S, Paul S, Chatterjee S, Bhattacharyya D, Behav Brain Res 2009 202 285 290 10.1016/j.bbr.2009.04.005 19375459
80. Nardostachys jatamansi improves learning and memory in mice. Joshi H, Parle M, J Med Food 2006 9 113 118 10.1089/jmf.2006.9.113 16579738 (Pubitemid 44153626)
81. A new hypolipidaemic agent (gugulipid). Das Gupta R, J Assoc Physicians India 1990 38 186 2380143
82. Gugulipid: pro-lipaemic effect. Gupta RD, J Assoc Physicians India 1990 38 598 2246214
83. GUGULIPID: a natural cholesterol-lowering agent. Urizar NL, Moore DD, Annu Rev Nutr 2003 23 303 313 10.1146/annurev.nutr.23.011702.073102 12626688 (Pubitemid 37059726)
84. In vivo protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1-42-induced oxidative stress. Perluigi M, Joshi G, Sultana R, Calabrese V, De Marco C, Coccia R, Cini C, Butterfield DA, J Neurosci Res 2006 84 418 426 10.1002/jnr.20879 16634068 (Pubitemid 44126294)
85. Ethyl ferulate, a lipophilic polyphenol, induces HO-1 and protects rat neurons against oxidative stress. Scapagnini G, Butterfield DA, Colombrita C, Sultana R, Pascale A, Calabrese V, Antioxid Redox Signal 2004 6 811 818 15345140 (Pubitemid 39237933)
86. Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA, J Neurochem 2005 92 749 758 10.1111/j.1471-4159.2004.02899.x 15686476 (Pubitemid 40229546)
87. Guggulsterone is a farnesoid × receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD, J Biol Chem 2003 278 10214 10220 10.1074/jbc.M209323200 12525500 (Pubitemid 36800282)
88. Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Saxena G, Singh SP, Pal R, Singh S, Pratap R, Nath C, Pharmacol Biochem Behav 2007 86 797 805 10.1016/j.pbb.2007.03.010 17477963 (Pubitemid 46829332)
89. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, Rader DJ, JAMA 2003 290 765 772 10.1001/jama.290.6.765 12915429 (Pubitemid 37432953)
90. A natural product that lowers cholesterol as an antagonist ligand for FXR. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD, Science 2002 296 1703 1706 10.1126/science.1072891 11988537 (Pubitemid 34579172)
91. Statins: drugs for Alzheimer's disease? Eckert GP, Wood WG, Muller WE, J Neural Transm 2005 112 1057 1071 10.1007/s00702-004-0273-1 15682268 (Pubitemid 40991521)
92. Brain cholesterol, statins and Alzheimer's disease. Kirsch C, Eckert GP, Koudinov AR, Muller WE, Pharmacopsychiatry 2003 36 Suppl 2 113 119 14574624
93. Cholesterol, lipids, amyloid beta, and Alzheimer's. Vestergaard M, Hamada T, Morita M, Takagi M, Curr Alzheimer Res 2010 7 262 270 10.2174/ 156720510791050821 19715550
94. Lipids and cognition. Morley JE, Banks WA, J Alzheimers Dis 2010 20 737 747 20413879
95. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Liu JP, Tang Y, Zhou S, Toh BH, McLean C, Li H, Mol Cell Neurosci 2010 43 33 42 10.1016/j.mcn.2009.07.013 19660552
96. Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Harris JR, Milton NG, Subcell Biochem 2010 51 47 75 10.1007/978-90-481-8622-8-2 20213540
97. Frawley D, Lad V, The Yoga of Herbs: An Ayurvedic Guide to Herbal Medicine Twin Lakes, WI: Lotus Press 1986
98. Intranasal drug delivery: how, why and what for? Pires A, Fortuna A, Alves G, Falcao A, J Pharm Pharm Sci 2009 12 288 311 20067706
99. Nasal route and drug delivery systems. Turker S, Onur E, Ozer Y, Pharm World Sci 2004 26 137 142 15230360 (Pubitemid 39012580)
100. Nasal drug delivery - possibilities, problems and solutions. Illum L, J Control Release 2003 87 187 198 10.1016/S0168-3659(02)00363-2 12618035 (Pubitemid 36255456)
101. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B, Arch Neurol 2012 69 29 38 10.1001/archneurol.2011.233 21911655
102. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. Dhuria SV, Hanson LR, Frey WH 2nd, J Pharm Sci 2010 99 1654 1673 19877171
103. A preliminary study of the effects of a single session of Swedish massage on hypothalamic-pituitary-adrenal and immune function in normal individuals. Rapaport MH, Schettler P, Bresee C, J Altern Complement Med 2010
104. Measurement of regional cerebral blood flow associated with the M technique-light massage therapy: a case series and longitudinal study using SPECT. Buckle J, Newberg A, Wintering N, Hutton E, Lido C, Farrar JT, J Altern Complement Med 2008 14 903 910 10.1089/acm.2007.0613 18990041
105. Effect of massage therapy on stress levels and quality of life in brain tumor patients - observations from a pilot study. Keir ST, Support Care Cancer 2011 19 711 715 10.1007/s00520-010-1032-5 21046417
106. Changes in cerebral blood flow under the prone condition with and without massage. Ouchi Y, Kanno T, Okada H, Yoshikawa E, Shinke T, Nagasawa S, Minoda K, Doi H, Neurosci Lett 2006 407 131 135 10.1016/j.neulet.2006.08.037 16973270 (Pubitemid 44397236)
107. Transcranial route of brain targeted delivery of methadone in oil. Pathirana W, Abhayawardhana P, Kariyawasam H, Ratnasooriya WD, Indian J Pharm Sci 2009 71 264 269 10.4103/0250-474X.56024 20490292
108. Nonpharmacological treatment of epilepsy. Saxena VS, Nadkarni VV, Ann Indian Acad Neurol 2011 14 148 152 10.4103/0972-2327.85870 22028523
109. Psychoneuroimmunologic effects of Ayurvedic oil-dripping treatment. Uebaba K, Xu FH, Ogawa H, Tatsuse T, Wang BH, Hisajima T, Venkatraman S, J Altern Complement Med 2008 14 1189 1198 10.1089/acm.2008.0273 19123874
110. Pharmaco-physio-psychologic effect of Ayurvedic oil-dripping treatment using an essential oil from Lavendula angustifolia. Xu F, Uebaba K, Ogawa H, Tatsuse T, Wang BH, Hisajima T, Venkatraman S, J Altern Complement Med 2008 14 947 956 10.1089/acm.2008.0240 18990044
111. The role of alternative medicine in treating postnatal depression. Mantle F, Complement Ther Nurs Midwifery 2002 8 197 203 10.1054/ctnm.2002.0647 12463609
112. Effect of aromatherapy on patients with Alzheimer's disease. Jimbo D, Kimura Y, Taniguchi M, Inoue M, Urakami K, Psychogeriatrics 2009 9 173 179 10.1111/j.1479-8301.2009.00299.x 20377818
113. Management of agitation and aggression associated with Alzheimer disease. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, Lyketsos CG, Nat Rev Neurol 2009 5 245 255 10.1038/nrneurol.2009.39 19488082